Tom Harold, Founder, Chief Executive Officer

Tom HaroldMr. Harold comes to ScyFix after 20 years of experience with many major, multi-national corporations as both an employee and consultant. Having founded several successful technology companies, Mr. Harold has helped many medical device companies bring their solutions to market. Beginning his career at General Mills, Tom progressed through several assignments, eventually serving as a marketing financial analyst for senior management. At Pillsbury, Mr. Harold held a variety of marketing management positions. Notably, Mr. Harold lead the fastest new product development effort in Pillsbury's history, consistently exceeded share, sales, and profit objectives, and was the youngest person at all of his successive levels of responsibility.

As Director of Marketing for Wilson Learning, Tom extended Wilson's number one share position internationally with sales growing at over 40% per year. As Senior Vice President at Roth Graham, Mr. Harold helped both emerging and very large clients with business and marketing strategy, promotion planning, marketing research, and database management.

Mr. Harold's entrepreneurial career includes time as Executive Vice President at NetRadio Network, 4ROI, and founder of Cirround and iPares. In his experience, Mr. Harold has helped Antares Pharma, Revlon, Campbell Foods, ConAgra, Cowels Media Corp., General Mills, The Quaker Oats Company, Motorola, Land O' Lakes, Pillsbury, Jostens, Guidant, Medtronic, Hoffman Engineering, Wells-Fargo, US Bank, M&M Mars, Nordic Track, Wilson Sporting Goods, Carlson Companies, Borden, 3M, Microsoft, IBM, DEC, GM, Pfizer, Northrup Aircraft, St. Paul Companies, USF&G, Glaxo Wellcome, Miracle Ear, Warner Lambert and Dow among others.

Tom has an MBA in Marketing Management from the University of Minnesota and a BBA in Finance from the University of Wisconsin.

Darrel DeMello, President

For more than 16 years, Dr. DeMello has established and grown medical device businesses Internationally for some of the world’s largest multi-national medical device & pharmaceutical companies including: Boston Scientific, Bard International, Lederle/Cyanamid, and Wyeth Laboratories Ltd. Prior to successively responsible management positions in the medical device & pharmaceutical industry, Dr. DeMello was a practicing medical doctor and surgeon. He has significant business experience and expertise in global sales, marketing, market development and business development in minimally invasive devices for cardiology, vascular diseases, gastroendoscopy, urology and neuro-interventions.

Beginning his medical device career at Wyeth laboratories, Dr. DeMello was the subject matter expert responsible for the medical rationale used for promotion campaigns, as well as training and development for both the field sales force and medical practitioners. At Lederle/Cyanamid, Dr. DeMello moved into product management where he lead a multi-functional “turn-around” team that in only 12 months brought the Pharmaceutical division back to profitability. At Bard International, Dr. DeMello advanced from clinical coordination and regulatory responsibilities to become the Sales Manager for South Asia. In his tenure, Bard established their businesses in India, Pakistan, Bangladesh, and Sri Lanka. Coronary Angioplasty cases grew from just 400 annually to more than 15,000 in India alone. In just a few years, this became a very profitable multi-million dollar business for Bard.

Dr. DeMello’s first position at Boston Scientific was as Area Director based in Bombay, India. In this first assignment, Dr. DeMello integrated 6 acquisitions into one cohesive business. He also changed the way the medical device business was conducted in India from an importer/distributor model to a direct sales organization model. Dr. DeMello also recruited and managed a 60 person team for Sales, Marketing, Finance, Operations, Distribution, Customer Service, and HR that achieved $10 million in sales in their first year of operation at a 58% profit margin. Dr. DeMello’s policies and procedures for ensuring safety stock levels at the hospital level, managing product complaints, payment terms, samples, trial and evaluation of products increased customer satisfaction which in turn increased revenue. In his next assignment, as Asia Pacific Regional Marketing Manager for Cardiology and Electrophysiology, Dr. DeMello introduced new and unique medical products to Asia, thus facilitating a major US medical device manufacturer to gain significant market leadership, sales, and profitability. Dr. DeMello is also credited with introducing Boston Scientific to the key opinion leaders in Australia, China, India, Taiwan, Malaysia/Singapore. He was responsible for physician training & physician advocacy programs across the region which involved bringing thought leaders for conferences from North America and Europe.

In charge of Emerging Technologies and New Business Development, Dr. DeMello was the “one-point” liaison between the USA headquarters and Europe, Japan, and Inter-Continental. In addition to launching new products and sales responsibility, the position also involved M&A activity.

 
     

Breaking News! The ScyFIX 700 MCN Therapy is the only patented Micro Current Neuromodulation (MCN) device approved in Europe for the treatment of Retinitis Pigmentosa. Compelling Clinical Results: Retinitis Pigmentosa (RP) is a degenerative disease, and improvement in visual fields, visual acuity, or contrast sensitivity is not expected. In the RP trial, best corrected visual acuity either improved or remained stable in 94% of patients and improved in 22% of the population. Visual field improved in 63% of the patients. Patients are now using mobile phones, reading newspapers, seeing faces of family members and threading needles, none of these day to day activities were possible for these patients before using the ScyFIX MCN device. Similar compelling results have been achieved in our Dry Age-Related Macular Degeneration (“ARMD”) trial as well.